展望在血液癌症中利用CAR T或NK细胞靶向巨噬细胞的前景
Looking ahead to targeting macrophages by CAR T- or NK-cells in blood cancers
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
影响因子:4.4
分区:医学2区 / 药学2区
发表日期:2024 Sep
作者:
David Kegyes, Paul Alexandru Milea, Andreea-Isabella Mazga, Adrian-Bogdan Tigu, Madalina Nistor, Diana Cenariu, Radu Tomai, Sanda Buruiana, Hermann Einsele, Alina Daniela Tănase, Ciprian Tomuleasa
DOI:
10.1080/14728222.2024.2400075
摘要
骨髓微环境（BME）对健康造血具有关键作用，但在血液恶性肿瘤中常受破坏。肿瘤相关巨噬细胞（TAMs）是肿瘤微环境（TME）中的主要细胞类型之一，在肿瘤生长与进展中起重要作用。靶向TAMs及调节其极化是癌症治疗的一种有前景的策略。本文讨论了TME的重要性及多种潜在靶点，包括：CD123、鞘氨醇1-磷酸受体、CD19/CD1d、CCR4/CCL22、CSF1R（CD115）、CD24、CD40、B7家族蛋白、MARCO、CD47、CD163、CD204、CD206及叶酸受体。革新性方法应对血液恶性肿瘤中免疫抑制微环境具有高度临床意义，可能提高生存率、改善生活质量并降低治疗毒性。未来的标准治疗很可能结合CAR T/NK细胞治疗与其他疗法，推动更全面的癌症治疗。
Abstract
The bone marrow microenvironment (BME) is critical for healthy hematopoiesis and is often disrupted in hematologic malignancies. Tumor-associated macrophages (TAMs) are a major cell type in the tumor microenvironment (TME) and play a significant role in tumor growth and progression. Targeting TAMs and modulating their polarization is a promising strategy for cancer therapy.In this review, we discuss the importance of TME and different multiple possible targets to modulate immunosuppressive TAMs such as: CD123, Sphingosine 1-Phosphate Receptors, CD19/CD1d, CCR4/CCL22, CSF1R (CD115), CD24, CD40, B7 family proteins, MARCO, CD47, CD163, CD204, CD206 and folate receptors.Innovative approaches to combat the immunosuppressive milieu of the tumor microenvironment in hematologic malignancies are of high clinical significance and may lead to increased survival, improved quality of life, and decreased toxicity of cancer therapies. Standard procedures will likely involve a combination of CAR T/NK-cell therapies with other treatments, leading to more comprehensive cancer care.